2023 Annual Meeting: Industry Product Sessions

These unique sessions provide exhibiting companies the opportunity to:
Present new research findings on products
Detail products
Conduct demonstrations
Highlight new products
These sessions are solely promotional and are not eligible for CME credit.
Session schedule
THEATER 1
Friday, March 17, 2023 | Exhibit Hall F
10:30 a.m. - 11:15 a.m.
When Self-Identity is Challenged in Dermatology: Clinical Implications for Alopecia Areata & Vitiligo
This multidisciplinary session will bring attention to the highly individualized burden of disease in AA and vitiligo in the context of culture, race, and religion, and the associated clinical implications.

12:00 p.m. - 12:45 p.m.
Uncovering the Critical Role of OX40 Signaling in Orchestrating Inflammation in Atopic Dermatitis
OX40 signaling can play a critical role in AD pathogenesis by driving T-cell-mediated effector and memory responses that orchestrate inflammation and disease chronicity.

1:30 p.m. - 2:15 p.m.
The Shades of Atopic Dermatitis in Skin of Color
Learn more about distinctive ways that atopic dermatitis (AD) may present in patients with skin of color. Learn about a treatment option that may help appropriate patients with uncontrolled moderate-to-severe AD.

3:00 p.m. - 3:45 p.m.
An Adjuvant Treatment Option for Certain Stages of Melanoma
Understand the recurrence rates in certain stages of melanoma from retrospective studies. Review efficacy and safety data for an adjuvant treatment for certain patients with completely resected melanoma.

THEATER 1
Saturday, March 18, 2023 | Exhibit Hall F
10:30 a.m. - 11:15 a.m.
A new game changer for the treatment of epidermal pigmentation: Reepot®
Reepot® is the world’s first target laser based on Q-switch 532nm, and control the hemoglobin chromophore that is related to side effects through a super-cooling control device by VSLS technology.

12:00 p.m. - 12:45 p.m.
Start Today, Without Delay: An Oral Treatment For Any Adult Patient With Plaque Psoriasis Regardless of Severity
Exploring the systemic nature and burden of plaque psoriasis, regardless of the extent of skin involvement. Highlighting earlier treatment considerations for appropriate patients who may need something more.

1:30 p.m. - 2:15 p.m.
Diagnosing and Assessing Prurigo Nodularis
Learn about the clinical presentation and diagnostic workup of prurigo nodularis (PN).

THEATER 1
Sunday, March 19, 2023 | Exhibit Hall F
10:30 a.m. - 11:15 a.m.
Alopecia Areata (AA): What You Need to Know
Reviews AA pathophysiology and the role of immune cells and inflammatory cytokines, provides an overview of methods to evaluate disease severity, and discusses the patient burden beyond hair loss.

12:00 p.m. - 12:45 p.m.
Targeted Biome Bacteriolysis - Novel Endolysin Addressing Undesired Staphylococcus aureus Colonization
Presented by GladskinMD

1:30 p.m. - 2:15 p.m.
A Breakthrough Treatment for Adult Patients With Generalized Pustular Psoriasis Flares
This program will review the diagnosis and treatment of GPP flares.

THEATER 2
Friday, March 17, 2023 | Exhibit Hall F
10:30 a.m. - 11:15 a.m.
Discussion on an Oral Treatment Option for Adult Patients with Moderate-to-Severe Plaque Psoriasis
This program describes the efficacy and safety profile of an oral product. You will learn more about the pivotal clinical trials, product function, and patient support services.

12:00 p.m. - 12:45 p.m.
Real Patient Stories: Taltz® (ixekizumab) Treatment Outcomes
This presentation includes a clinical overview of disease manifestations, clinical efficacy, and safety outputs from relevant pivotal trials. The facilitator will provide clinical insights and be available for a live Q&A session.

3:00 p.m. - 3:45 p.m.
A game-changing discovery for Skincare: Novel postbiotic bioactive Urolithin A (MitopureR) slows both intrinsic and extrinsic skin aging
Topical solutions that are safe and improve cellular health during aging are needed. Findings on Urolithin A, a postbiotic molecule that reverses intrinsic and extrinsic skin aging will be presented.

THEATER 2
Saturday, March 18, 2023 | Exhibit Hall F
10:30 a.m. - 11:15 a.m.
Join Pfizer: Learn About an Oral RX Treatment for Moderate-to-Severe Atopic Dermatitis

12:00 p.m. - 12:45 p.m.
Step into Possibility: Discover Olumiant - The first FDA-approved systemic treatment for adults with severe alopecia areata (AA)
This presentation includes a clinical overview of disease manifestations, clinical efficacy, and safety outputs from relevant pivotal trials. The facilitator will provide clinical insights and be available for a live Q&A session.

1:30 p.m. - 2:15 p.m.
Creating a World-First ‘Matrikine’ Peptide Blend with No7
With 86 years of innovation, No7 is unveiling a novel matrix-derived peptide blend created with skin scientists at the University of Manchester; following 15 years of research into skin aging and repair.

3:00 p.m. - 3:45 p.m.
The newest effective and tolerable solution for Rosacea

THEATER 2
Sunday, March 19, 2023 | Exhibit Hall F
10:30 a.m. - 11:15 a.m.
Join us to learn about the multidisciplinary management of advanced CSCC and locally advanced BCC.
Regeneron is a leading science-based biopharmaceutical company that invents, develops and commercializes medicines to treat serious medical conditions.

12:00 p.m. - 12:45 p.m.
ParaPRO’s Thought Leader AI
Join Dr. Christina Feser, DO, FAAD, FAOCD as she engages “live” with digital human avatars of the leading experts on the topic of scabies. It’s the future of scientific exchange!
